Skip to main content
Signal8

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

$LIMNPress releaseJun 30, 2026, 4:30 PM ETRead the release

Liminatus Pharma amended its definitive merger agreement with InnocsAI to allow the deal to close prior to stockholder approval, with an expected closing date of July 2, 2026. The transaction implies a value of approximately $320 million, with consideration consisting of common stock issued at $0.20 per share and non-voting convertible preferred stock. InnocsAI equity holders will receive up to 19.99% of Liminatus' outstanding common stock immediately at closing.

Key figures

Deal Value Usd
$320 million
Offering Price
0.2
Closing date
July 2, 2026
Cvr percentage
20% of future net proceeds from strategic transactions
Immediate dilution cap
19.99% of outstanding common stock

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.